163 results on '"Urso, Loredana"'
Search Results
2. Mesothelin-Targeted Agents in Mesothelioma
3. Targeted Therapies in Mesothelioma
4. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
5. Metabolic rewiring and redox alterations in malignant pleural mesothelioma
6. Figure S2 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
7. Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
8. Table S5 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
9. Supplementary Figure Legend from miR-212 Increases Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Sensitivity in Non–Small Cell Lung Cancer by Targeting the Antiapoptotic Protein PED
10. Supplementary Figure 1 from miR-212 Increases Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Sensitivity in Non–Small Cell Lung Cancer by Targeting the Antiapoptotic Protein PED
11. Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
12. Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
13. Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment
14. Editorial:Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets
15. Synergistic Antitumor Activity of Recombinant Human Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) in Combination with Carboplatin and Pemetrexed in Malignant Pleural Mesothelioma
16. mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells
17. The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers
18. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
19. Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification
20. ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
21. Supplementary Table 1
22. P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
23. PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
24. Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
25. Metabolic rewiring and redox alterations in malignant pleural mesothelioma
26. Sublethal concentrations of the platinum(II) complex [Pt(O,O′–acac)(γ–acac)(DMS)] alter the motility and induce anoikis in MCF–7 cells
27. Anti-apoptotic effects of protein kinase C-δ and c-fos in cisplatin-treated thyroid cells
28. Functions of epidermal growth factor receptor in cisplatin response of thyroid cells
29. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
30. New platinum(II) complexes containing both an O,O′-chelated acetylacetonate ligand and a sulfur ligand in the platinum coordination sphere induce apoptosis in HeLa cervical carcinoma cells
31. Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment
32. Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC.
33. PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
34. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
35. Sublethal concentrations of [Pt(O,O’-acac)(γ-acac)(DMS)]alter the motility capability and exert anoikis of MCF-7 cellsthrough the p38/MAPK pathway
36. [Pt(O,O’-acac)(γ-acac)(DMS)] induces apoptosis in human breast cancer cells in primary culture
37. Role of epidermal growth factor receptor in the response to cisplatin in malignant rat thyroid PC E1Araf cells
38. Cytotoxicity of [Pt(O,O’-acac)(γ-acac)(DMS)] in normal and cancerous human breast cells in primary culture
39. A new platinum (II) complex exerts higher cytotoxicity in tumoral than in normal human breast cells in primary culture
40. [Pt(O,O’-acac)(γ-acac)(DMS)] affects the intracellular Ca2+ homeostasis in MCF-7 breast cancer cells
41. Overcoming the cisplatin resistance: a promising strategy of new beta-diketonate Pt(II) complexes with sulfur ligand as leaving group
42. Differential activation of ERK1/2 in human breast cancer MCF-7 cells treated with cisplatin or [Pt(O,O’-acac)(γ-acac)(DMS)]
43. Different regulation of matrix metalloproteinase-2 in cisplatin response of normal and transformed thyroid cells
44. [Pt(O,O’-acac)(γ-acac)(DMS)] exerts high and fast cytotoxicity in breast cancer cells in primary culture
45. Mitochondria-mediated apoptosis by a new Pt(II) compound, [Pt(O,O’-acac)(g-acac) (DMS)], in human breast cancer cells
46. A new platinum(II) complex with high cytotoxicity in human breast cancer MCF-7 cells
47. Involvement of Protein Kinase C-delta and -epsylon in cisplatin-induced apoptosis in thyroid cells
48. Involvement of Protein Kinase Cdelta and -epsilon in cisplatin-induced apoptosis in thyroid cells
49. Cisplatin-analogous β-diketonate Pt(II) organometallic species: reactivity and cytotoxicity
50. A new platinum(II) complex with high cytotoxicity in human endometrial cancer HeLa cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.